Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trial

Lai Wei,† Ji Dong Jia,† Zhong Ping Duan,‡ Fu Sheng Wang,§ Jun Qi Niu,¶ Wen Xie,‖ Wen Xiang Huang,**, Ming Xiang Zhang,†† Yan Huang,†† Mao Rong Wang,‡‡ Shan Ming Wu,¶¶ Ying Ren Zhao,††† Zhan Sheng Jia,*** Xu Min Zhao,‡§ Sheng Mei Mu,‡§ Li Wen Liang,‡§ Zaizi Wang,‡§ Amy Puenpatom,‡§ Peggy Hwang,‡§ Michael N. Robertson,*,‡ O Paul Ingravallo,*,§ Ernest Asante-Appiah,*,† Bo Wei,*,§ Barbara Evans,*,§ George J. Hanna,*,†© and Rohit Talwani,*,†

*Beijing Key Laboratory for Hepatitis C and Immunotherapeutic for Liver Disease, Peking University People’s Hospital, Peking University Hepatology Institute, †Beijing Key Laboratory of Translational Medicine on Cirrhosis, National Clinical Research Center for Digestive Diseases, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, ‡Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, ‡‡Treatment and Research Center for Infectious Diseases, Beijing 302 Hospital, ‡§Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, †Department of Hepatology, First Hospital, Jilin University, Changchun, ††Division of Microbiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, †††Department of Integrated Traditional and Western Medicine on Liver Diseases, The Sixth People’s Hospital of Shenyang, Shenyang, ‡‡Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, ‡§Center of Liver Disease, The 81st Hospital of PLA, Nanjing, †††Department of Infectious Diseases, Shanghai Public Health Center, Shanghai, ‡§Department of Infectious Disease, First Affiliated Hospital of Medicine College, Xi’an Jiaotong University, ***Center of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi’an, China, ‡‡Department of Infectious Diseases, MSD, China, Beijing and *Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, New Jersey, USA

Key words
hepatitis C virus clinical trials, hepatitis C clinical, viral hepatitis, virology, hepatitis C virus treatment.

Accepted for publication 18 June 2020.

Correspondence
Dr Michael N. Robertson, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Email: michael Robertson@merck.com

Declaration of conflict of interest: Lai Wei reports consulting fees from Merck, Sharp & Dohme (China), AbbVie, Bristol-Myers Squibb, Gilead, Allergan, and Johnson & Johnson and grants from AbbVie, Bristol-Myers Squibb, and Roche. Ji Dong Jia reports consulting and lecture fees from AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, and Merck, Sharp & Dohme (China). Xu Min Zhao, Sheng Mei Mu, and Li Wen Liang are employees of MSD, China. Barbara Evans, Amy Puenpatom, Peggy Hwang, Ernest Asante-Appiah, and Rohit Talwani are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Michael N. Robertson, Paul Ingravallo, Bo Wei, and George J. Hanna are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and report stock ownership in Merck & Co., Inc., Kenilworth, NJ, USA. Zhong Ping Duan, Fu Sheng Wang, Jun Qi Niu, Wen Xie, Wen Xiang Huang, Michael N. Robertson, Paul Ingravallo, Bo Wei, and George J. Hanna are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, USA.

Abstract
Background and Aim: In China, clinical experience with direct-acting antiviral treatments for hepatitis C virus (HCV) infection is still emerging. C-CORAL is a phase 3, multinational, placebo-controlled, double-blind trial of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from the Asia-Pacific region and Russia. Here, we report the data from participants enrolled in China.

Methods: Treatment-naive participants with chronic HCV genotype (GT) 1, GT4, or GT6 infection were randomly assigned to receive 50 mg EBR/100 mg GZR for 12 weeks (immediate-treatment group, ITG) or placebo followed by deferred treatment with EBR/GZR (deferred-treatment group, DTG). The primary efficacy endpoint was sustained virologic response at 12 weeks after completing treatment (SVR12), and the primary safety endpoint was a comparison of safety between participants receiving EBR/GZR or placebo.

Results: A total of 152 participants in China were randomly assigned (ITG, n = 115; DTG, n = 37). SVR12 was achieved in 96.7% (146/151) participants overall and in 97.3% (142/146) of those with GT1b infection. Four participants relapsed (GT1b, n = 3; GT6a, n = 1). Drug-related AEs were reported in 25 (21.7%) and 9 (24.3%) participants receiving EBR/GZR or placebo, respectively; no drug-related serious adverse events (AEs) occurred. Two (1.7%) participants receiving EBR/GZR had elevated hepatic transaminase elevations. Patient-reported outcomes indicate improved quality of life at follow-up week 4 in participants receiving EBR/GZR compared to placebo.

Conclusion: EBR/GZR administered for 12 weeks represents a highly effective and safe treatment option for Chinese individuals with HCV GT1 infection.
Introduction

In China, nearly 9 million people have hepatitis C virus (HCV) infection, amounting to 0.8% of the total population. In fact, there are more adults with HCV infection in China than in any other country worldwide, predominantly with HCV genotype (GT) 1b (57%), GT2 (15%), or GT3 (9%) infection. While the use of direct-acting antiviral (DAAs) regimens has dramatically improved the treatment of people with HCV infection, clinical experience with these therapies in China is still emerging, and to date, asunaprevir, simprevir, and the combinations of daclatasvir/asunaprevir and ombitasvir/dasabuvir plus paritaprevir/ritonavir have been approved in China.

Elbasvir (EBR) plus grazoprevir (GZR) is a once-daily fixed-dose combination treatment that is approved in many Western countries for the treatment of HCV GT1 and GT4 infection and in Japan for HCV GT1 infection. EBR and GZR are potent antiviral agents in vitro and were shown to be safe and effective in phase 2/3 clinical studies. The safety profile of EBR/GZR was similar in participants with and without cirrhosis and was also similar to that seen in participants who received placebo treatment. Notably, sustained virologic response (SVR) at 12 weeks after completing treatment (SVR12) was high in participants with HCV GT1b infection.

The aim of the C-CORAL study was to assess the safety and efficacy of a 12-week regimen of EBR/GZR in participants with HCV infection from countries in the Asia-Pacific region and Russia. This publication describes the data from participants enrolled in mainland China.

Methods

The C-CORAL study was a placebo-controlled, randomized, double-blind, phase 3 study conducted at 49 centers in mainland China (15), South Korea (6), Vietnam (3), Thailand (3) and Australia (2) (Appendix 1). Data from participants enrolled outside China have been reported separately. This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines (ClinicalTrials.gov Identifier: NCT02251990). The protocol was reviewed and approved by institutional review boards or ethics committees at each institution and is available online as a supplementary file (Protocol PN-5172-067). All participants provided informed consent prior to any study-related procedures. The study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Participants. Participants aged ≥18 years with chronic HCV GT1, GT4, or GT6 infection and baseline HCV RNA ≥10,000 IU/mL were enrolled at 13 study sites in China. Treatment-naïve persons with and without cirrhosis were eligible, with cirrhosis defined based on liver biopsy (METAVIR F4 within 24 months of enrollment), Fibroscan (a reading of >12.5 kPa within 12 months of enrollment), or a combination of FibroTest (>0.75) and aspartate aminotransferase (AST):platelet ratio index (AST:PI) (≥2). Participants with evidence of human immunodeficiency virus (HIV) coinfection, chronic hepatitis B infection, or evidence of decompensated liver disease were excluded.

Study design. Participants were randomly assigned in a 3:1 ratio to receive immediate or deferred treatment with EBR/GZR. Participants in the immediate-treatment group (ITG) received once-daily 50 mg EBR/100 mg GZR for 12 weeks. Participants in the deferred-treatment group (DTG) received once-daily placebo for 12 weeks followed by a 4-week blinded follow-up period and then open-label EBR/GZR for 12 weeks.

A centrally located interactive voice response system/integrated web response system was used to perform randomization, and participant enrollment was stratified based on the presence or absence of cirrhosis and country of enrollment (China vs South Korea vs Taiwan vs Russia vs other). Participants, site personnel, and the sponsor were blinded through week 16, at which time treatment allocation was unblinded, and participants in the DTG received active therapy.

Procedures. Plasma HCV RNA levels were analyzed using the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, version 2.0 (Roche Molecular Diagnostics, Branchburg, NJ, USA; lower limit of quantitation (LLoQ) = 15 IU/mL). HCV genotype was evaluated with the Abbott HCV Real Time Genotype II assay (Abbott Diagnostics, Chicago, IL, USA). HCV subtyping was determined for non-GT1b samples by a published template-independent next-generation sequencing assay.

End-points. The primary efficacy end-point was SVR12, defined as the percentage of participants in the ITG with HCV RNA < LLoQ at 12 weeks after completion of treatment. Virologic failure was defined as nonresponse (HCV RNA > LLoQ...
throughout treatment and at the end of treatment), rebound (>1 log₁₀ increase in HCV RNA from nadir during treatment), breakthrough (HCV RNA > LLoQ after being < LLoQ during treatment), or relapse (HCV RNA > LLoQ during follow-up after having HCV RNA < LLoQ at end of treatment). SVR24 was evaluated as a secondary outcome. The primary safety outcome was a comparison of safety events between the ITG and DTG during the initial 12-week placebo-controlled period and up to 14 days after unblinding. Safety events recorded were adverse events (AEs), vital signs, and laboratory test results. Late elevations in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) were defined as ALT/AST >5 × the upper limit of normal (ULN) after treatment week (TW) 4 in participants with ALT/AST ≤ ULN between weeks 2 and 4. Drug resistance was evaluated in participants with virologic failure and HCV RNA >2000 IU/mL.

Health-related quality of life (HRQOL) was assessed at baseline, TW4, end of treatment, and follow-up week 4 using the Short Form-36v2 (SF-36v2®) survey,24 the EuroQol-5D-5L (EQ-5D-5L),25 and the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACT-Fatigue Scale), Version 4.26 The acute, 1-week recall version of the SF-36v2 was used to detect recent changes in health status. The SF-36v2 measures each of the following eight health domains: Role Limitations-Physical, Physical Functioning, Bodily Pain, Vitality, General Health, Social Functioning, Mental Health, and Role Limitations-Emotional, which contribute to the computation of the mental and physical component summaries (MCS and PCS, respectively). The EuroQol EQ-5D-5L is a validated, standardized 5-item health-state questionnaire (self-care, mobility, usual activities, anxiety/depression, and pain/discomfort), in which participants rate their current general state of health, from “the worst health you can imagine” to “the best health you can imagine” using a graded (0–100) visual analog scale (EQ VAS). The FACT-Fatigue Scale is a 13-item self-report questionnaire using a 5-point Likert-type response scale to measure fatigue (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much), with a recall period of “during the past 7 days.”

**Statistical analysis.** The planned enrollment was 453 participants from Russia and the Asia-Pacific region, with a prespecified interim analysis planned for participants enrolled in the ITG at centers outside China. The study was not powered for an assessment of efficacy in the China cohort. Overall enrollment of participants in China was not to exceed 10% of the target. A total of 250 participants were randomly assigned to the ex-China ITG, leaving a maximum of 124 Chinese participants to be enrolled.

The full analysis set population (FAS, all randomly assigned participants who received ≥1 dose of study treatment) was used for the primary efficacy analysis. A two-sided 95% asymptotic confidence interval (CI) was calculated for SVR12 in the ITG. Evaluation of safety events was performed in all participants who received ≥1 dose of study drug.

Descriptive summary statistics are provided for change in HRQOL scores from baseline. Analyses were based on the FAS population, missing data were not imputed, and no multiplicity adjustment was applied.

**Results**

A total of 180 participants were screened in China, of whom 27 failed screening and 1 withdrew prior to randomization. The
remaining 152 participants were randomly assigned (ITG, n = 115; DTG, n = 37) (Fig. 1). The first participant started treatment on 18 March 2016, and the last participant in the ITG completed 12 weeks of follow-up on 27 September 2016. All participants in the ITG completed 12 weeks of treatment and 12 weeks of follow-up. One participant in the ITG discontinued between follow-up week (FW) 12 and FW24 owing to an AE of lymphoma. Of the 37 participants randomly assigned to the DTG, one discontinued during placebo treatment because of an AE, and a second participant withdrew consent after completing 12 weeks of active deferred therapy (Fig. 1).

Most participants had GT1b infection (96.7%, 147/152) and had F0–F2 fibrosis (73.7%, 112/152) (Table 1). Approximately half of all enrolled participants had baseline HCV RNA

### Table 1 Baseline demographics

| Characteristic                     | ITG EBR/GZR 12 weeks (n = 115) | DTG placebo for 12 weeks (n = 37) | All participants (N = 152) |
|------------------------------------|---------------------------------|-----------------------------------|---------------------------|
| Gender, n (%)                      |                                 |                                   |                           |
| Male                               | 55 (47.8)                       | 17 (45.9)                         | 72 (47.4)                 |
| Female                             | 60 (52.2)                       | 20 (54.1)                         | 80 (52.6)                 |
| Age, years                         |                                 |                                   |                           |
| Mean (SD)                          | 44.4 (13.6)                     | 43.5 (14.1)                       | 44.1 (13.7)               |
| Median (range)                     | 46.0 (20–77)                    | 45.0 (22–76)                      | 45.0 (20–77)              |
| Race, n (%)                        |                                 |                                   |                           |
| Asian                              | 115 (100.0)                     | 37 (100.0)                        | 152 (100.0)               |
| HCV genotype, n (%)                |                                 |                                   |                           |
| GT1b                               | 106 (92.2)                      | 35 (94.6)                         | 141 (92.8)                |
| GT1-other                          | 5 (4.3)                         | 1 (2.8)                           | 6 (4.0)                   |
| GT6*                               | 4 (3.5)                         | 1 (2.8)                           | 5 (3.3)                   |
| BMI, n (%)                         |                                 |                                   |                           |
| <30 kg/m²                          | 109 (94.8)                      | 35 (94.6)                         | 144 (94.7)                |
| ≥30 kg/m²                          | 6 (5.2)                         | 2 (5.4)                           | 8 (5.3)                   |
| Baseline HCV RNA, n (%)            |                                 |                                   |                           |
| ≤800 000 IU/mL                     | 32 (27.8)                       | 9 (24.3)                          | 41 (27.0)                 |
| >800 000 IU/mL                     | 83 (72.2)                       | 28 (75.7)                         | 111 (73.0)                |
| ≤2 000 000 IU/mL                   | 59 (51.3)                       | 16 (43.2)                         | 75 (49.3)                 |
| >2 000 000 IU/mL                   | 56 (48.7)                       | 21 (56.8)                         | 77 (50.7)                 |
| ≤10 000 000 IU/mL                  | 111 (96.5)                      | 36 (97.3)                         | 147 (96.7)                |
| >10 000 000 IU/mL                  | 4 (3.5)                         | 1 (2.7)                           | 5 (3.3)                   |
| IL28B genotype (rs12979860)        |                                 |                                   |                           |
| CC                                 | 89 (77.4)                       | 29 (78.4)                         | 118 (77.6)                |
| Non-CC                             | 26 (22.6)                       | 7 (18.9)                          | 33 (21.7)                 |
| Missing                            | 0 (0)                           | 1 (2.7)                           | 1 (0.6)                   |
| METAVIR stage, n (%)               |                                 |                                   |                           |
| F0–F2                              | 85 (73.9)                       | 27 (73.0)                         | 112 (73.7)                |
| F3                                 | 10 (8.7)                        | 4 (10.8)                          | 14 (9.2)                  |
| F4                                 | 20 (17.4)                       | 6 (16.2)                          | 26 (17.1)                 |
| Cirrhosis†, n (%)                  |                                 |                                   |                           |
| Yes                                | 20 (17.4)                       | 6 (16.2)                          | 26 (17.1)                 |
| By biopsy                          | 3 (2.6)                         | 0 (0)                             | 3 (2.0)                   |
| By FibroScan                       | 17 (14.8)                       | 6 (16.2)                          | 23 (15.1)                 |
| No                                 | 95 (82.6)                       | 31 (83.8)                         | 126 (82.9)                |
| By biopsy                          | 24 (20.9)                       | 9 (24.3)                          | 33 (21.7)                 |
| By FibroTest                       | 1 (0.9)                         | 0 (0)                             | 1 (0.7)                   |
| By FibroScan                       | 70 (60.9)                       | 22 (59.5)                         | 92 (60.5)                 |
| Hemoglobin, mean (SD), g/dL        | 14.3 (1.5)                      | 14.3 (1.7)                        | 14.3 (1.5)                |
| Albumin, mean (SD), g/dL           | 4.78 (0.33)                     | 4.84 (0.34)                       | 4.80 (0.33)               |
| Bilirubin, mean (SD), g/dL         | 0.75 (0.38)                     | 0.76 (0.27)                       | 0.75 (0.36)               |

*All five HCV GT6 samples were subtyped as HCV GT6a by template-independent next-generation sequencing assay.

†A total of 27 participants in the ITG had liver fibrosis stage based on liver biopsy. The majority of participants in the ITG (n = 87) had fibrosis stage assigned based on transient elastography: FibroScan scores <8.0 kPa were interpreted as F0–F2 fibrosis, scores of 8.0–12.5 kPa were considered METAVIR F3 fibrosis, and scores >12.5 kPa were interpreted as METAVIR F4.

Data are n (%) unless otherwise indicated.

BMI, body mass index; DTG, deferred-treatment group; EBR, elbasvir; GT, genotype; GZR, grazoprevir; HCV, hepatitis C virus; ITG, immediate-treatment group; IU, international units; SD, standard deviation.
2,000,000 IU/mL (50.7%, 77/152). Overall, 23 of 26 participants with cirrhosis had their fibrosis stage diagnosed by FibroScan®.

Efficacy

In the FAS population, the SVR12 rate was 96.7% (146/151), with similar rates achieved in the ITG (97.4%, 112/115) and DTG (94.4%, 34/36) (Fig. 2). SVR12 was achieved by 97.1% (136/140) and 80% (4/5) of participants with HCV GT1b and GT6a infection, respectively. Six participants did not achieve SVR12, including one participant in the DTG who discontinued during placebo treatment because of AEs of chest discomfort, headache, and oral hypoesthesia. This participant did not receive a dose of EBR/GZR and was excluded from the FAS population for efficacy analyses. Five participants in the FAS population failed to achieve SVR12. One participant from the DTG withdrew consent after completing 12 weeks of active therapy, and four participants relapsed (ITG, n = 3 [GT1b, n = 2; GT6, n = 1]; DTG, n = 1 [GT1b, n = 1]). All relapses occurred prior to FW12, and no virologic failures occurred between FW12 and FW24. SVR12 rates were high in most subgroups evaluated, including 88.5% (23/26) in participants with cirrhosis, 94.7% (72/76) in participants with baseline viral load >2,000,000 IU/mL, and 85.7% (5/6) in participants aged ≥65 years (Fig. 3).

Of 140 participants with HCV GT1b infection in the FAS, one withdrew, and the remaining 139 were eligible for inclusion in the resistance analysis. Of 139 participants, 35 (25.2%) had at least one baseline NS5A resistance-associated substitution (RAS) at amino acid position 28, 30, 31, or 93, of whom 32 achieved SVR12 (91.4%). All 104 participants with HCV GT1b infection and no baseline NS5A RASs at positions 28, 30, 31, or 93 achieved SVR12. Three participants with HCV GT1b infection relapsed. All had a baseline NS5A RAS at position 93 and were selected for either 28 M, 31 I, or 31 M at failure. The participant with HCV GT6 who relapsed had no identified baseline NS5A RAS and no treatment-emergent NS5A RAS at failure.

The only difference between virologic outcomes at FW12 and FW24 (i.e. SVR12 and SVR24) was a single participant in the ITG who discontinued between FW12 and FW24 with an AE of lymphoma. Thus, SVR24 was achieved by 96.0% of participants (145/151).

| Variable                  | n/N | % (95% CI) |
|---------------------------|-----|-----------|
| All participants          | 146/151 | 96.7 (92.4, 98.9) |
| HCV genotype              |     |           |
| GT1b                      | 136/140 | 97.1 (92.8, 99.2) |
| GT1-other                 | 6/6  | 100.0 (54.1, 100.0) |
| GT6                       | 4/5   | 80.0 (28.4, 99.5) |
| Sex                       |     |           |
| Male                      | 69/72 | 95.8 (88.3, 99.1) |
| Female                    | 77/79 | 97.5 (91.2, 99.7) |
| Age                       |     |           |
| <65 years                 | 139/144 | 96.5 (92.1, 98.9) |
| ≥65 years                 | 7/7   | 100.0 (59.0, 100.0) |
| Cirrhosis                 |     |           |
| No                        | 122/125 | 97.6 (93.1, 99.5) |
| Yes                       | 24/26 | 92.3 (74.9, 99.1) |
| Baseline viral load       |     |           |
| ≤800,000 IU/mL            | 40/41 | 97.6 (87.1, 99.9) |
| >800,000 IU/mL            | 106/110 | 96.4 (91.0, 99.0) |
| ≤2,000,000 IU/mL          | 74/75 | 98.7 (92.8, 100.0) |
| >2,000,000 IU/mL          | 72/76 | 94.7 (87.1, 98.5) |
| ≤10,000,000 IU/mL         | 141/146 | 96.6 (92.2, 98.9) |
| >10,000,000 IU/mL         | 5/5   | 100.0 (47.8, 100.0) |

SVR12 (95% CI)
Safety

EBR/GZR was generally well tolerated, with a safety profile similar to that of placebo (Table 2). The incidence of AEs was similar in participants receiving EBR/GZR and those receiving placebo (DTG-placebo; 51.3% vs 48.6%, respectively). The most common AEs in participants receiving EBR/GZR and placebo, respectively, were upper respiratory tract infection (7.8% vs 10.8%), diarrhea (5.2% vs 10.8%), fatigue (7.0% vs 2.7%), and dizziness (7.0% vs 2.7%). Drug-related AEs were reported in 25 (21.7%) participants receiving EBR/GZR in the ITG and 9 (24.3%) of those receiving placebo in the DTG; the most common were diarrhea (3.5% vs 8.1%) and fatigue (5.2% vs 2.7%). Serious AEs (SAEs) were reported by three participants (2.6%) in the ITG (Evans syndrome, lymphoma, and enteritis) and one participant (2.7%) receiving placebo in the DTG (foot fracture). All were considered unrelated to study drug. No deaths or drug-related SAEs occurred in either treatment arm. One participant in the DTG receiving placebo discontinued treatment owing to AEs of chest discomfort, headache, and oral hypoesthesia, which were considered drug-related and not serious.

Four hepatic laboratory events of clinical interest (ECIs) were reported, two each in the ITG (1.7%, 2/115) and the placebo phase of the DTG (5.4%, 2/37). Both hepatic ECIs in the ITG were late ALT/AST elevations (>5 × ULN after TW4, after having a normal ALT between TW2 and TW4), and in both participants, ALT/AST levels returned to within normal limits during treatment or soon after treatment was completed. Narratives for these participants are provided in Appendix 2. Neither of these participants had concomitant increased bilirubin levels or discontinued study medication because of the protocol-specified stopping rule for hepatic laboratory abnormalities. No other hepatic laboratory abnormalities or symptoms of hepatic impairment were reported. Overall, transaminase elevations that were attributed to EBR/GZR were infrequent and reversible and were unlikely to be accompanied by other laboratory abnormalities or clinical symptoms.

The safety profile of EBR/GZR for 12 weeks was also similar in participants in the DTG when receiving deferred EBR/GZR for 12 weeks. AEs were reported in 14 (38.9%) participants, and three participants reported a total of four drug-related AEs (ALT increased, AST increased, conjugated bilirubin increased, and blood bilirubin increased). None of these drug-
related AEs met the criteria to be considered hepatic ECIs. No participant receiving deferred active therapy discontinued treatment, and no SAEs or deaths occurred.

Health-related quality of life

At baseline, SF36v2 scores were similar in participants receiving EBR/GZR and those receiving placebo (Supplementary Fig. 1A). Baseline scores were numerically higher (indicating better quality of life) in the DTG-placebo compared with the ITG in all domains, except the General Health domain. The difference in mean change from baseline between ITG and DTG-placebo (immediate – deferred) at TWs 4 and 12 suggested no consistent improvement in any domain, with 95% CIs for mean differences including zero for all domains (Fig. 4a). At FW4, differences in mean change from baseline suggested improvements in patients treated with EBR/GZR compared with placebo. Participants receiving EBR/GZR showed mean improvements of between 7.1% and 11.0% at FW4 compared with change from baseline in placebo recipients for all eight individual domains and with 95% CIs that did not include zero. PCS and MCS scores also showed improvements in HRQOL in EBR/GZR recipients of 3–4% relative to placebo recipients and again with 95% CIs that did not include zero.

Baseline scores on the EQ-VAS and FACIT-Fatigue scale were similar in the ITG and DTG-placebo (Supplementary Fig. 1B). A similar profile of response was also seen with the EQ-VAS and FACIT-Fatigue scale, with the difference in mean change from baseline (ITG – DTG) at TW4 and TW12 showing no difference between treatment groups but with both scales also showing notable improvements in quality of life in participants receiving EBR/GZR compared with placebo at FW4. At FW4, treatment difference (ITG – DTG) mean change from baseline was 6.31% (95% CI, 1.93%, 10.70%) for the EQ-VAS and 4.12% (95% CI, 1.94%, 6.30%) for the FACIT-Fatigue scale, indicating benefits associated with EBR/GZR therapy in terms of general health and fatigue.

Discussion

EBR/GZR is a safe and effective treatment option for people with HCV GT1 or GT4 infection in many countries worldwide. The results from the present study confirm that EBR/GZR also represents an effective treatment option for treatment-naïve Chinese patients with HCV GT1 infection. In this study, the SVR12 rate was 96.7% overall and 97.3% in those with GT1b
infection. Baseline characteristics, such as presence of cirrhosis and high baseline viral load, had no impact on SVR12. The safety profile of EBR/GZR in the present study was also generally comparable to the safety profile in studies in Western regions that included a deferred-treatment arm.13,19,20 Finally, patient-reported outcomes data indicate improved HRQOL in patients receiving EBR/GZR compared with placebo at 4 weeks after completion of therapy. Given the very high rates of SVR among participants in the ITG receiving EBR/GZR (compared with no participants in the ITG receiving placebo), these improvements in HRQOL are likely a reflection of clearance of HCV.

In the United States and Europe, testing for resistance variants at baseline is not required in people with HCV GT1b infection starting treatment with EBR/GZR.3–5 This practice is supported by data from an integrated analysis of participants with GT1b infection who were enrolled in the phase 2/3 clinical studies of EBR/GZR.21 In this analysis of 1070 participants with GT1b infection (of whom 462 [43.2%] were Asian), the overall SVR12 rate was 97.2% (1040/1070), with rates of 99.6% (820/823) in those with no baseline NS5A RASs at amino acid position 28, 30, 31, or 93 and 94.7% (215/227) in those with baseline NS5A RASs. Similarly, in the analysis of participants from the C-CORAL study enrolled in countries outside China, SVR rates were high in participants with GT1b infection with and without baseline NS5A RASs (97.4% [38/39] vs 100% [146/146]).22 The high rates of SVR12 (97.3%) reported in Chinese participants with HCV GT1b infection in the present study are consistent with rates in previous analyses in individuals with HCV GT1b infection.

The present study did not enrol people with previous treatment experience, and the numbers of participants with HCV genotypes other than GT1b were low. In Western countries, the efficacy and safety of EBR/GZR has been established comprehensively only in people with HCV GT1 or GT4 infection. Most participants in the present study also had mild liver disease, and only 17% had well-compensated Child-Pugh A cirrhosis. Few participants underwent biopsy, and in most, cirrhosis was identified using transient elastography. Although transient elastography scores are known to correlate well with cirrhosis, it is worth noting that there is also substantial overlap of liver stiffness values between adjacent fibrosis stages, particularly in individuals with milder fibrosis.27 People with decompensated liver disease were not enrolled in this study. Studies in Western participants indicate high rates of SVR12 in those with compensated cirrhosis, possibly owing to the higher-than-normal plasma levels of GZR seen in people with cirrhosis.28

In conclusion, results from the C-CORAL study support the use of EBR/GZR for the treatment of HCV GT1 infection in treatment-naive individuals in China. Based on these results, the safety and efficacy profile of EBR/GZR appears consistent with that previously reported in Western populations13 and Japanese people with HCV GT1 or GT4 infection. These data also indicate that achieving SVR following treatment with EBR/GZR is associated with improved HRQOL.

Acknowledgments
The authors extend their gratitude to the participants, their families, investigators, and site personnel who participated in this study. Medical writing and editorial assistance were provided by Tim Ibbotson, PhD, of ApotheCom (Yardley, PA, USA) and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The studies included in this analysis were funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Data sharing statement
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA’s data sharing policy, including restrictions, is available at http://engagezone.msd.com/ds-documentation.php. Requests for access to the clinical study data can be submitted through the EngageZone site or via email to dataaccess@merck.com.

References
1 Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 2014; 61: S45–S57.
2 Zhao H, Wei L, Lopez-Talavera JC et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J. Gastroenterol. Hepatol. 2014; 29: 545–553.
3 Zepatier [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp. 2018.
4 Zepatier [summary of product characteristics]. Hoddesdon, Hertfordshire, UK: Merck Sharp & Dohme Ltd. 2018.
5 Health Canada. Summary Basis of Decision (SBD) for Zepatier. Drug Identification Number: 02451131. Ontario, Canada: Ottawa, 2016. Cited 27 March 2018. Available from: https://health-products.canada.ca/dpd-bdp/info.do?lang=en&code=93740.
6 Coburn CA, Meinke PT, Chang W et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013; 8: 1930–40.
7 Harper S, McCauley JA, Rudd MT et al. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. ACS Med. Chem. Lett. 2012; 3: 332–6.
8 Summa V, Ludmerer SW, McCauley JA et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 2012; 56: 4161–7.
9 Lahser FC, Bystol K, Curry S et al. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob. Agents Chemother. 2016; 60: 2954–64.
10 Liu R, Curry S, McMonagle P et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob. Agents Chemother. 2015; 59: 6922–9.
11 Lawitz E, Gane E, Pearlman B et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385: 1075–86.
12 Sulkowski M, Hezode C, Gerosto J et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385: 1087–97.
13 Zeuzem S, Ghalib R, Reddy KR et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients
with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. *Ann. Intern. Med.* 2015; **163**: 1–13.

14 Roth D, Nelson DR, Bruchfeld A *et al.* Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. *Lancet.* 2015; **386**: 1537–45.

15 Rockstroh JK, Nelson M, Katlama C *et al.* Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFEC-TION): a non-randomised, open-label trial. *Lancet HIV.* 2015; **2**: e319–27.

16 Kwo P, Gane E, Peng CY *et al.* Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. *Gastroenterology.* 2016; **152**: 164–75.

17 Sperl J, Horvath G, Halota W *et al.* Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. *J. Hepatol.* 2016; **65**: 1112–9.

18 Forns X, Gordon SC, Zuckerman E *et al.* Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. *J. Hepatol.* 2015; **63**: 564–72.

19 Dore GJ, Altice F, Litwin AH *et al.* Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. *Ann. Intern. Med.* 2016; **165**: 625–34.

20 Hezode C, Colombo M, Bourliere M *et al.* Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. *Hepatology.* 2017; **66**: 736–45.

21 Zeuzem S, Serfaty L, Vietling J *et al.* The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. *J. Gastroenterol.* 2018; **53**: 679–88.

22 George J, Burnevich E, Sheen IS *et al.* Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. *Hepatol Commun.* 2018; **2**: 595–606.

23 Wei B, Kang J, Kibukawa M *et al.* Development and validation of a template-independent next-generation sequencing assay for detecting low-level resistance-associated variants of hepatitis C virus. *J. Mol. Diagn.* 2016; **18**: 643–56.

24 Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. *Hepatology.* 2005; **41**: 790–800.

25 Herdman M, Gudex C, Lloyd A *et al.* Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual. Life Res.* 2011; **20**: 1727–36.

26 Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. *J. Pain Symptom Manage.* 1997; **13**: 63–74.

27 EASL-ALEH. Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J. Hepatol.* 2015; **63**: 237–64.

28 Jacobson IM, Lawitz E, Kwo PY *et al.* Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. *Gastroenterology.* 2017; **152**: 1372–82.

29 Kumada H, Suzuki Y, Karino Y *et al.* The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. *J. Gastroenterol.* 2017; **52**: 520–33.

**Supporting information**

Additional supporting information may be found in the online version of this article at the publisher’s website:

**Appendix S1.** Supporting information.